IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

JARAI ET AL.

APPLICATION NO:

FILED:

FOR: INFLAMMATION RELATED G-PROTEIN COUPLED RECEPTOR

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed with the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/930,334 filed August 15, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis

Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080

(862) 778-7809

Date: 7/14/13

1. Halli Ul Bravillello B. Gabrielle Brouillette

Agent for Applicants

Reg. No. 51,384

Sheet 1 of 2

FORM PTO-1449 (REV. 7-85)

EXAMINER

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-31553B/HO 33 APPLICATION NO. Not Yet Known APPLICANT JARAI ET AL. FILING DATE Herewith

Group

			U.S.	PATENT DOCUMENTS				
XAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CL	ASS SUBCLA	SS F	ILING DATI
	AA							-
	АВ							
	AC	.,						
	AD							
****	AE							_
	AF		-					
	AG							
	АН							
	Al							
	AJ							
_	AK	. 43						
	AL							
			FOREIG	ON PATENT DOCUMENTS				
_		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN	ISLATIC
	АМ	97/07209	2/27/97	WO				
	AN	00/22129	4/20/00	wo				
	AO							
	AP							
	AQ							
	AQ	OTHER DOC	UMENTS	(Including Author, Title, Date, Pertin	ent pages, E	Etc.)		
-	<u> </u>	Nomura et al., "Molec	ular cloning	of cDNAs encoding a LD78 re	ceptor and	putative leul		
	AQ	Nomura et al., "Molec	ular cloning		ceptor and	putative leul		3).
	<u> </u>	Nomura et al., "Molec chemotactic peptide r	ular cloning eceptors", I	of cDNAs encoding a LD78 re	ceptor and 5, No. 10, p	putative leul pp. 1239-124	9 (199	
	AR	Nomura et al., "Molecchemotactic peptide r Frazer et al., "RDA of (1997).	ular cloning eceptors", I lymphocyte	of cDNAs encoding a LD78 re nternational Immunology, Vol. (ceptor and 5, No. 10, p ogical Meth ent Delaye	putative leuk pp. 1239-124 nods, Vol. 20 d Neutrophil	9 (199 7, pp. 1	1-12 osis: <i>F</i>

DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

À

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-31553B/HO 33 APPLICATION NO. Not Yet Known APPLICANT JARAI ET AL. FILING DATE Herewith

Group

INITIAL	ОТН	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)					
	ВА	Stadel et al., "Orphan G Protein-Coup Discovery", TiPs, Vol. 18, pp. 430-437	led Receptors: A Neglected Opportunity for Pioneer Drug (1997).				
	BB	Fitzgerald et al., "Measurement of Res Multiple Response Element/cAMP Re Biochemistry, Vol. 275, pp. 54-61 (199	sponses from Gi-, Gs-, or Gq-Coupled Receptors by a sponse Element-Directed Reporter Assay", Analytical 99).				
	ВС	Schaub et al., "PUMA-G, an IFN-γ-Inc	ucible Gene in Macrophages is a Novel Member of the ceptor Superfamily", Eur. J. Immunol., Vol. 31, pp. 3714-3725				
	BD		s", The Journal of Biological Chemistry", Vol. 273, No. 28, pp.				
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	BE	Kaplan, "Chemokines, Chemokine Re No. 4, pp. 423-431 (2001).	ceptors and Allergy", Int. Arch. Allergy Immunol., Vol. 124,				
	BF						
-	BG						
	ВН						
	ВІ						
	BJ						
	вк						
	BL						
	вм						
	BN						
EXAMINER			DATE CONSIDERED				

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.